Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CH.1.1.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.55NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.14NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AP.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.98.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.13.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.34.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.124.1.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.203NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.8.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GY.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.7.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.254NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.36.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.21NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.122.2 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.79 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
AQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.1.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.209NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.236NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XQNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.59NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.395NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.120.2.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.416.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.532NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.408NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XHNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.423NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.550NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.261NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.3.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EP.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.15.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XCBNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.15.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.8.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XSNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.38NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.160.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.74NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used